Matches in Wikidata for { <http://www.wikidata.org/entity/Q94522475> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- Q94522475 description "artículu científicu espublizáu en mayu de 2020" @default.
- Q94522475 description "im Mai 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q94522475 description "scientific article published on 04 May 2020" @default.
- Q94522475 description "wetenschappelijk artikel" @default.
- Q94522475 description "наукова стаття, опублікована 4 травня 2020" @default.
- Q94522475 name "Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients" @default.
- Q94522475 name "Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients" @default.
- Q94522475 type Item @default.
- Q94522475 label "Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients" @default.
- Q94522475 label "Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients" @default.
- Q94522475 prefLabel "Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients" @default.
- Q94522475 prefLabel "Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients" @default.
- Q94522475 P1433 Q94522475-0D45FBFF-1A18-431C-A663-6D572D041B37 @default.
- Q94522475 P1476 Q94522475-F967A2E7-85FD-4DE5-92CA-EB74B200F4C1 @default.
- Q94522475 P2093 Q94522475-0D10E01F-A601-4D69-BA41-D8107989AF6E @default.
- Q94522475 P2093 Q94522475-1323F0C7-9797-46F6-AC24-A367904C749C @default.
- Q94522475 P2093 Q94522475-1EEF0658-3A50-4B50-86A6-42B27CB7BB3E @default.
- Q94522475 P2093 Q94522475-4A2DEA99-7C4D-4F47-B79B-B13E59AB6F4F @default.
- Q94522475 P2093 Q94522475-4ED8CC06-7D74-4707-8C4E-E26E6874BC61 @default.
- Q94522475 P2093 Q94522475-5BA80971-73EE-4C5A-887D-F9FE76D6B30E @default.
- Q94522475 P2093 Q94522475-5CE81A8E-3D54-4267-BD37-CFD110628D48 @default.
- Q94522475 P2093 Q94522475-7C2D125B-0036-42D4-B89C-61AD25E0FBA0 @default.
- Q94522475 P2093 Q94522475-843336E2-9EC0-4D94-A54A-6A63F08EEE39 @default.
- Q94522475 P2093 Q94522475-8CA2FA91-9F68-4BF4-AD5E-FDBFA69F3278 @default.
- Q94522475 P2093 Q94522475-920675F5-647F-4A27-8BCD-FECEFED86011 @default.
- Q94522475 P2093 Q94522475-AD91E29B-77B3-422C-AE17-ABD0C61403E3 @default.
- Q94522475 P2093 Q94522475-B305FE63-770C-4968-B0AD-F4FF133ABC14 @default.
- Q94522475 P2093 Q94522475-DFEDF964-7D5C-4C7E-985A-3073EAC7ED99 @default.
- Q94522475 P31 Q94522475-232E14CC-2D2C-4FAE-9407-2CBC330B54FD @default.
- Q94522475 P356 Q94522475-2C84ABFF-C493-4B6D-90F5-C520D648FD68 @default.
- Q94522475 P577 Q94522475-6C3BA3F1-D9BD-46D7-AA69-CD2ED934FD51 @default.
- Q94522475 P698 Q94522475-DCD0B1C9-1B38-47D8-987C-52A0460F3984 @default.
- Q94522475 P921 Q94522475-27E11B16-6BBC-432B-B1C6-0C95143B5431 @default.
- Q94522475 P921 Q94522475-E95D6918-72C2-4B86-983D-E4DDCE1A14D8 @default.
- Q94522475 P356 S00277-020-04056-9 @default.
- Q94522475 P698 32367180 @default.
- Q94522475 P1433 Q15766509 @default.
- Q94522475 P1476 "Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients" @default.
- Q94522475 P2093 "Alberto Fernández de Sevilla" @default.
- Q94522475 P2093 "Andres López" @default.
- Q94522475 P2093 "Andres Muñoz" @default.
- Q94522475 P2093 "Antonio Salar" @default.
- Q94522475 P2093 "Carlos Panizo" @default.
- Q94522475 P2093 "Eva Domingo-Domenech" @default.
- Q94522475 P2093 "Eva González-Barca" @default.
- Q94522475 P2093 "Francisco Javier Capote" @default.
- Q94522475 P2093 "GELTAMO (Spanish Lymphoma Group) and GOTEL (Group of Oncology for Therapy and Study of Lymphomas)" @default.
- Q94522475 P2093 "Javier Briones" @default.
- Q94522475 P2093 "Jose Gómez-Codina" @default.
- Q94522475 P2093 "Juan-Manuel Sancho" @default.
- Q94522475 P2093 "Maite Encuentra" @default.
- Q94522475 P2093 "Santiago Mercadal" @default.
- Q94522475 P31 Q13442814 @default.
- Q94522475 P356 "10.1007/S00277-020-04056-9" @default.
- Q94522475 P577 "2020-05-04T00:00:00Z" @default.
- Q94522475 P698 "32367180" @default.
- Q94522475 P921 Q412323 @default.
- Q94522475 P921 Q42824440 @default.